FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year

Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year

Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024

Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER

Reducing non-GAAP Operating Expense Guidance to $340M to $350M

Conference Call and Webcast Today at 8:30 a.m. ET

PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024.

“The third quarter of the year was marked by the excellent commercial performance of our two approved therapies and continued financial discipline,” said Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc. “Strong patient demand for Galafold drove double digit revenue growth, while the commercial launch of Pombiliti and Opfolda continues to build momentum. We also announced a settlement of the Galafold (migalastat) patent litigation with Teva, which is a major step forward in ensuring Amicus can continue to support the Fabry community with Galafold for many years to come. Importantly, throughout the first nine months of the year, we’ve exceeded expectations, which resulted in the achievement of non-GAAP profitability for the full year 2024 as we closed the third quarter. Amicus continues to be well positioned to drive sustainable shareholder value and further our mission of delivering great medicines for people living with rare diseases.”

Financial and Corporate Highlights:

  • Total revenue in the third quarter 2024 was $141.5 million, a year-over-year increase of 37% from total revenue of $103.5 million in the third quarter 2023. On a constant currency basis (CER)1, third quarter 2024 total revenue growth was 36%.

(in thousands)Three Months Ended

September 30,
 Year over Year %

Growth
 Nine Months Ended

September 30,
 Year over Year %

Growth
 2024 2023 Reported at CER1 2024 2023 Reported at CER1
Galafold®$120,381 $100,733 20% 19% $330,557 $281,177 18% 18%
Pombiliti® + Opfolda®$21,136 $2,768 664% 658% $48,032 $3,097 1451% 1442%
Net Product Revenues$141,517 $103,501 37% 36% $378,589 $284,274 33% 33%
                
  • Galafold (migalastat) net product sales were $120.4 million in the third quarter 2024, a year-over-year increase of 20%, or 19% at constant exchange rates1, reflecting continued strong demand. Given strong performance in the first nine months of 2024, the Company is raising its full year 2024 revenue growth guidance for Galafold to +16% to +18% on a constant currency basis (CER)1.
  • Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) net product sales were $21.1 million in the third quarter 2024, a 33% increase from the second quarter of 2024. As of the end of October, 203 patients have been treated or are scheduled to be treated with commercial product in five markets (USA, Germany, UK, Spain, and Austria). Given strong launch momentum, the Company is raising its full year 2024 revenue guidance for Pombiliti + Opfolda to $69 million to $71 million on a constant currency basis (CER)1.
  • Total GAAP operating expenses of $106.6 million for the third quarter 2024 decreased by 4% as compared to $110.6 million for the third quarter 2023. Total non-GAAP operating expenses of $82.6 million for the third quarter 2024 decreased by 8% as compared to $89.8 million for the third quarter 2023. Given continued financial discipline in the first nine months of 2024, the Company is reducing its non-GAAP Operating Expense guidance3 to $340 million to $350 million.
  • GAAP net loss was $6.7 million, or $0.02 per share, for the third quarter 2024, and was reduced compared to a net loss of $21.6 million, or $0.07 per share, for the third quarter 2023.
  • Non-GAAP net income was $30.8 million, or $0.10 per share, for the third quarter 2024, compared to a non-GAAP net loss of $4.0 million, or $0.01 per share, for the third quarter 20232. Non-GAAP profitability was also achieved in the first nine months of 2024.
  • Cash, cash equivalents, and marketable securities totaled $249.8 million at September 30, 2024, compared to $286.2 million at December 31, 2023.
  • In October 2024, the Company announced that it has entered into a License Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. allowing Teva to market a generic version of Galafold® in the United States beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration (FDA) and unless certain limited circumstances customarily included in these types of agreements occur. Similar patent litigation previously disclosed by the Company will continue against Aurobindo (Aurobindo Pharma LTD and Aurobindo Pharma USA, Inc.) as the remaining active party and the litigation stay remains in place for Lupin (Lupin LTD and Lupin Pharmaceuticals, Inc.).

2024 Financial Guidance:

 Previous Updated
Total Revenue Growth126% to 31%30% to 32%
Galafold Revenue Growth114% to 18%16% to 18%
Pombiliti + Opfolda Revenue1$62M to $67M$69M to $71M
Non-GAAP Operating Expense3$345M to $360M$340M to $350M
    

Amicus is focused on the following key strategic priorities in 2024:

  • Delivering double-digit Galafold revenue growth
  • Executing multiple successful launches of Pombiliti + Opfolda
  • Advancing ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases
  • Achieving full-year non-GAAP profitability4

1 At constant exchange rates (CER). In order to illustrate underlying performance, Amicus discusses its results in terms of CER growth. This represents growth calculated as if the exchange rates had remained unchanged from those used in the comparative period. Full-year revenue guidance utilizes actual exchange rate as of December 31, 2023.

2 Full reconciliation of GAAP results to the Company’s non-GAAP adjusted measures for the reporting period(s) appear in the tables to this press release.

3 A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity, and low visibility as to the items that would be excluded from the GAAP measure.

4 Based on projections of Amicus’ non-GAAP Net (Loss) Income under current operating plans, which includes successful Pombiliti + Opfolda launch and continued Galafold growth. Amicus defines non-GAAP Net (Loss) Income as GAAP Net (Loss) Income excluding the impact of share-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition-related income (expense), loss on extinguishment of debt, restructuring charges and income taxes.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and audio webcast today, November 6, 2024, at 8:30 a.m. ET to discuss the third quarter 2024 financial results and corporate updates. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a PIN number to access the event.

A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at . Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Galafold 

Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of people living with Fabry disease may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in more than 40 countries around the world, including the U.S., EU, U.K., and Japan.

U.S. INDICATIONS AND USAGE

Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

U.S. IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.

USE IN SPECIFIC POPULATIONS

There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or .

For additional information about Galafold, including the full U.S. Prescribing Information, please visit .

About Pombiliti + Opfolda

Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that’s designed to reduce loss of enzyme activity in the blood.

U.S. INDICATIONS AND USAGE

POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).

SAFETY INFORMATION

HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION: POMBILITI in combination with Opfolda is contraindicated in pregnancy. EMBRYO-FETAL TOXICITY: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose. Adverse Reactions: Most common adverse reactions ≥ 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia. Please see full PRESCRIBING INFORMATION, including BOXED WARNING, for POMBILITI (cipaglucosidase alfa-atga) and full PRESCRIBING INFORMATION for OPFOLDA (miglustat) .

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information, please visit the Company’s website at , and follow on and .

Non-GAAP Financial Measures

In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We use these non-GAAP measures as key performance measures for the purpose of evaluating operational performance and cash requirements internally. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses and profitability on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities and pricing and reimbursement authorities, are based on current information. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that required regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in negotiations with pricing and reimbursement authorities; the potential that we may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the UK, the US and other geographies; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies, the manufacturing, and commercialization of our products. With respect to statements regarding corporate financial guidance and financial goals and the expected attainment of such goals and projections of the Company's revenue, non-GAAP profitability and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2023, and on Form 10-Q for the quarter ended September 30, 2024, to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations

(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Affairs and Communications

(609) 662-5079

FOLD-G



TABLE 1        

Amicus Therapeutics, Inc.

Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

 Three Months Ended September 30, Nine Months Ended September 30,
  2024   2023   2024   2023 
Net product sales$141,517  $103,501  $378,589  $284,274 
Cost of goods sold 13,279   9,946   38,107   26,002 
Gross profit 128,238   93,555   340,482   258,272 
Operating expenses:       
Research and development 26,160   40,704   79,172   117,352 
Selling, general, and administrative 75,106   65,651   236,711   205,031 
Changes in fair value of contingent consideration payable    1,995      2,583 
Restructuring charges 3,143      9,188    
Loss on impairment of assets          1,134 
Depreciation and amortization 2,170   2,228   6,506   5,691 
Total operating expenses 106,579   110,578   331,577   331,791 
Income (loss) from operations 21,659   (17,023)  8,905   (73,519)
Other expense:       
Interest income 1,081   1,471   3,991   5,407 
Interest expense (12,692)  (12,986)  (37,640)  (37,322)
Other (expense) income (3,263)  3,833   (11,946)  (13,007)
Income (loss) before income tax 6,785   (24,705)  (36,690)  (118,441)
Income tax (expense) benefit (13,514)  3,128   (34,155)  700 
Net loss attributable to common stockholders$(6,729) $(21,577) $(70,845) $(117,741)
Net loss attributable to common stockholders per common share — basic and diluted$(0.02) $(0.07) $(0.23) $(0.40)
Weighted-average common shares outstanding — basic and diluted 304,690,596   295,759,435   303,792,479   293,314,167 
                

TABLE 2

Amicus Therapeutics, Inc.

Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

 September 30, 2024 December 31, 2023
Assets   
Current assets:   
Cash and cash equivalents$233,647  $246,994 
Investments in marketable securities 16,110   39,206 
Accounts receivable 98,073   87,632 
Inventories 115,338   59,696 
Prepaid expenses and other current assets 35,306   49,533 
Total current assets 498,474   483,061 
Operating lease right-of-use assets, net 23,144   26,312 
Property and equipment, less accumulated depreciation of $29,324 and $25,429 at September 30, 2024 and December 31, 2023, respectively 30,438   31,667 
Intangible assets, less accumulated amortization of $4,974 and $2,510 at September 30, 2024 and December 31, 2023, respectively 18,026   20,490 
Goodwill 197,797   197,797 
Other non-current assets 18,678   18,553 
Total Assets$786,557  $777,880 
Liabilities and Stockholders’ Equity   
Current liabilities:   
Accounts payable$13,481  $15,120 
Accrued expenses and other current liabilities 136,116   144,245 
Operating lease liabilities 8,541   8,324 
Total current liabilities 158,138   167,689 
Long-term debt 389,494   387,858 
Operating lease liabilities 46,623   48,877 
Other non-current liabilities 13,477   13,282 
Total liabilities 607,732   617,706 
Commitments and contingencies   
Stockholders’ equity:   
Common stock, $0.01 par value, 500,000,000 shares authorized, 298,691,094 and 293,594,209 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 2,942   2,918 
Additional paid-in capital 2,905,760   2,836,018 
Accumulated other comprehensive income (loss):   
Foreign currency translation adjustment 25,159   5,429 
Unrealized loss on available-for-sale securities (188)  (188)
Warrants 71   71 
Accumulated deficit (2,754,919)  (2,684,074)
Total stockholders’ equity 178,825   160,174 
Total Liabilities and Stockholders’ Equity$786,557  $777,880 
        

TABLE 3

Amicus Therapeutics, Inc.

Reconciliation of Non-GAAP Financial Measures

(in thousands)

(Unaudited)

 Three Months Ended

September 30,
 Nine Months Ended

September 30,
  2024  2023  2024  2023
Total operating expenses - as reported GAAP$ 106,579 $ 110,578 $ 331,577 $ 331,791
Research and development:       
Stock-based compensation 4,397  4,380  12,329  16,987
Selling, general and administrative:       
Stock-based compensation 14,291  12,131  53,359  50,995
Loss on impairment of assets       1,134
Changes in fair value of contingent consideration payable    1,995    2,583
Restructuring Charges 3,143    9,188  
Depreciation and amortization 2,170  2,228  6,506  5,691
Total operating expense adjustments to reported GAAP 24,001  20,734  81,382  77,390
Total operating expenses - as adjusted$82,578 $89,844 $250,195 $254,401
            



TABLE 4

Amicus Therapeutics, Inc.

Reconciliation of Non-GAAP Financial Measures

(in thousands, except share and per share amounts)

(Unaudited)

  Three Months Ended

September 30,
 Nine Months Ended

September 30,
   2024   2023   2024   2023 
         
GAAP net loss $(6,729) $(21,577) $(70,845) $(117,741)
Share-based compensation  18,688   16,511   65,688   67,982 
Changes in fair value of contingent consideration payable     1,995      2,583 
Depreciation and amortization  2,170   2,228   6,506   5,691 
Loss on impairment of assets           1,134 
Restructuring charges  3,143      9,188    
Income tax expense (benefit)  13,514   (3,128)  34,155   (700)
Non-GAAP net income (loss) $30,786  $(3,971) $44,692  $(41,051)
         
Non-GAAP net income (loss) attributable to common stockholders per common share — basic and diluted $0.10  $(0.01) $0.15  $(0.14)
Weighted-average common shares outstanding — basic and diluted  304,690,596   295,759,435   303,792,479   293,314,167 


EN
06/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and...

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

 PRESS RELEASE

Amicus Therapeutics to Present at Upcoming Investor Conferences in Nov...

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ETJefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT A live audio webcast of each presentation can also be accessed via the investors section of ...

 PRESS RELEASE

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results o...

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access...

 PRESS RELEASE

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Pat...

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic vers...

 PRESS RELEASE

Amicus Therapeutics Announces Participation at the World Muscle Societ...

Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the being held October 8-12, 2024 in Prague, Czechia. Poster Session: Pompe Disease Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P) Presenter: Barry J. Byrne, MD, PhD, University of Flori...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch